The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries
Abstract
Background The first and second EUROASPIRE surveys showed high rates of modifiable cardiovascular risk factors in patients with coronary heart disease. The third EUROASPIRE survey was done in 2006-07 in 22 countries to see whether preventive cardiology had improved and if the Joint European Societies' recommendations on cardiovascular disease prevention are being followed in clinical practice.Methods EUROASPIRE I, II, and III were designed as cross-sectional studies and included the same selected geographical areas and hospitals in the Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, and Slovenia. Consecutive patients (men and women </=70 years) were identified after coronary artery bypass graft or percutaneous coronary intervention, or a hospital admission with acute myocardial infarction or ischaemia, and were interviewed at least 6 months later.Findings 3180 patients were interviewed in the first survey, 2975 in the second, and 2392 in the third. Overall, the proportion of patients who smoke has remained nearly the same (20.3% in EUROASPIRE I, 21.2% in II, and 18.2% in III; comparison of all surveys p=0.64), but the proportion of women smokers aged less than 50 years has increased. The frequency of obesity (body-mass index >/=30 kg/m(2)) increased from 25.0% in EUROASPIRE I, to 32.6% in II, and 38.0% in III (p=0.0006). The proportion of patients with raised blood pressure (>/=140/90 mm Hg in patients without diabetes or >/=130/80 mm Hg in patients with diabetes) was similar (58.1% in EUROASPIRE I, 58.3% in II, and 60.9% in III; p=0.49), whereas the proportion with raised total cholesterol (>/=4.5 mmol/L) decreased, from 94.5% in EUROASPIRE I to 76.7% in II, and 46.2% in III (p<0.0001). The frequency of self-reported diabetes mellitus increased, from 17.4%, to 20.1%, and 28.0% (p=0.004).Interpretation These time trends show a compelling need for more effective lifestyle management of patients with coronary heart disease. Despite a substantial increase in antihypertensive and lipid-lowering drugs, blood pressure management remained unchanged, and almost half of all patients remain above the recommended lipid targets. To salvage the acutely ischaemic myocardium without addressing the underlying causes of the disease is futile; we need to invest in prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gap between state-of-the-art knowledge and its implementation in clinical practice remains wide, as shown in recent surveys such as EUROASPIRE III. 5”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [5]
In the citing paper
“There is still substantial room for improvement in risk factor control, even in individuals at very high risk.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [5]
In the citing paper
“While audits such as EUROASPIRE 5,38,39 suggest inadequate risk factor management in very-high-risk subjects”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [5]
In the citing paper
“Moreover, the changes between EUROASPIRE I (1996) and EUROASPIRE III reveal that the proportion of smokers did not change and BP control has not improved despite increased use of antihypertensive drugs, while the number of patients with (central) obesity continues to increase.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [5]
In the citing paper
“On the other hand, lipid control has improved significantly. 5”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [5]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
Taylor, R. S., Brown, A., Ebrahim, S., Jolliffe, J., Noorani, H., Rees, K., Skidmore, B., Stone, J. A., Thompson, D. R., & Oldridge, N. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.01.009 · Cited by 2,239
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Self-citationbeta Blockade after myocardial infarction: systematic review and meta regression analysis
Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J. (1999) · BMJ · doi:10.1136/bmj.318.7200.1730 · Cited by 1,509
European cardiovascular disease statistics
Allender, S. E., Scarborough, P., Peto, V., Rayner, M., Leal, J., Luengo-Fernández, R., & Gray, A. M. (2008) · Deakin Research Online (Deakin University) · Cited by 1,459
Research works printed but not linked: 2
- De Backer, 2003, Eur J Cardiovasc Prev Rehabil, 10, S1
- De Velasco, 1997, Secondary prevention of myocardial infarction in Spain. The PREVESE study, Rev Esp Cardiol, 50, 406
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationMancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Higgins, S. M. F., Macken, A. P., Cullen, W., Saunders, J., Dunne, C. P., & O’Gorman, C. S. (2013) · PubMed · doi:10.34961/9953 · Cited by 4,806
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Self-citation
Metadata
- Authors
- Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U.
- Affiliations
- Imperial College London (GB)
- University of Münster (DE)
- Corresponding author
- Wood, David
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 373
- Issue
- 9667
- Pages
- 929-940
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2142264046
- Cited by
- 833
- References
- 49
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 18 · 2020: 16 · 2019: 20 · 2018: 29 · 2017: 47 · 2016: 44 · 2015: 88 · 2014: 78 · 2013: 83 · 2012: 88
- FWCI
- 119.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
- Funders
- European Society of Cardiology
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- cardiovascular disease prevention, coronary artery disease, cardiovascular risk factors, smoking, obesity, hypertension, hypercholesterolemia, diabetes mellitus, preventive cardiology, guideline adherence, secondary prevention, coronary artery bypass grafting, percutaneous coronary intervention, acute myocardial infarction, ischemia, older adults, cross-national comparison
- MeSH terms
- Smoking Prevention, Aged, Cardiovascular Diseases, Cross-Sectional Studies, Diet, Europe, Female, Health Surveys, Humans, Hypercholesterolemia, Life Style, Male, Middle Aged, Obesity, Risk Factors, Smoking, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60330-5
- The paper
- Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U. (2009). Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. The Lancet. https://doi.org/10.1016/s0140-6736(09)60330-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.